The abundance of cellular fibronectin (c-Fn) for ischemic stroke patients and the narrow time-window (<4.5 h) for the decision to administer the thrombolytic treatment with recombinant tissue plasminogen activator (rtPA) are challenging for the development of a point-of-care (PoC) diagnostic platform. We report a case of stratification of ischemic stroke patients based on a magnetoresistive biosensor platform that quantifies the c-Fn levels in a small volume of serum, within the clinically relevant time-window. Our PoC platform uses different ratios of biofunctionalized magnetic nanoparticles (MNPs) as immunoassay labels to adjust the sensitivity within the clinically relevant ranges for c-Fn (1-4 μg/mL). After optimizing the detection range, resolution, and sensitivity, our device was able to stratify ischemic stroke patients who developed hemorrhagic transformation, the main side-effect of rtPA, from those (both non-treated and treated with rtPA) who did not.

缺血性卒中患者的细胞纤连蛋白 (c-Fn) 丰富，而且决定使用重组组织纤溶酶原激活剂 (rtPA) 进行溶栓治疗的时间窗很窄（<4.5 小时），这对开发点-护理 (PoC) 诊断平台。我们报告了一个基于磁阻生物传感器平台对缺血性中风患者进行分层的案例，该平台在临床相关的时间窗口内量化了少量血清中的 c-Fn 水平。我们的 PoC 平台使用不同比例的生物功能化磁性纳米粒子 (MNP) 作为免疫测定标签，在 c-Fn (1-4 μg/mL) 的临床相关范围内调整灵敏度。优化检测范围、分辨率和灵敏度后，